- ISIN
- KYG9442G1047
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 23, 2021
Highlights
- Market Cap
- $2.00M
- Enterprise Value
- -$8.63M
- EPS (TTM)
- -$1.51
- Total Revenue (TTM)
- $37.04M
- Gross Profit (TTM)
- $12.35M
- EBITDA (TTM)
- $502.65K
- Year Range
- $2.00 - $17.96
- ROA (TTM)
- -1.19%
- ROE (TTM)
- -1.53%
- Avg. Volume (1M)
- 912K
- Avg. Volume Value (1M)
- $3.84M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
UPC Performance Chart
Universe Pharmaceuticals INC (UPC) is down 17.1% since the beginning of the year. At $3 per share, UPC is trading 82.4% below its 52-week high of $18. Investors who bought $1,000 worth of UPC shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Universe Pharmaceuticals INC (UPC) has returned -17.06% so far this year and -9.20% over the past 12 months.
Universe Pharmaceuticals INC
- 1D
- -9.20%
- 1M
- -50.00%
- 6M
- -28.51%
- YTD
- -17.06%
- 1Y
- -9.20%
- 3Y*
- -85.75%
- 5Y*
- -79.41%
- 10Y*
- —
- ALL TIME*
- -80.29%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
UPC Monthly Returns History
Based on dividend-adjusted daily data since Mar 23, 2021, UPC's average daily return is -0.03%, while the average monthly return is -5.11%.
Historically, 37% of months were positive and 63% were negative. The best month was Dec 2023 with a return of +137.9%, while the worst month was Sep 2024 at -92.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.
On a daily basis, UPC closed higher 42% of trading days. The best single day was Jun 29, 2026 with a return of +311.5%, while the worst single day was Sep 13, 2024 at -67.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.01% | -38.46% | 1.10% | 17.43% | 8.38% | 74.29% | -48.20% | -17.06% | |||||
| 2025 | -33.61% | -68.47% | -19.73% | 16.59% | -1.67% | -20.21% | -5.67% | 0.26% | 18.43% | 12.38% | -16.53% | -3.30% | -84.39% |
| 2024 | 3.98% | -10.05% | 16.49% | 10.05% | 21.29% | -14.81% | 48.19% | -11.92% | -92.49% | 7.66% | -54.83% | -65.73% | -97.98% |
| 2023 | -41.39% | -29.39% | -3.02% | -17.35% | 20.58% | -37.93% | -3.68% | -32.71% | -32.14% | 17.89% | -24.57% | 137.93% | -76.90% |
| 2022 | -14.37% | -12.14% | 2.86% | -5.94% | -7.57% | -42.95% | 1.07% | -19.56% | 10.74% | 92.04% | 66.82% | -19.89% | -11.31% |
| 2021 | -23.76% | -8.23% | -12.77% | -1.25% | -25.24% | -2.11% | 6.47% | -8.10% | -4.85% | -24.31% | -68.92% |
Benchmark Metrics
Universe Pharmaceuticals INC has an annualized alpha of -12.80%, beta of 0.37, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since March 23, 2021.
- This stock participated in 258.48% of S&P 500 Index downside but only -119.60% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.37 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -12.80%
- Beta
- 0.37
- R²
- 0.00
- Upside Capture
- -119.60%
- Downside Capture
- 258.48%
Return for Risk
Risk / Return Rank
UPC ranks 61 for risk / return — above 61% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Universe Pharmaceuticals INC (UPC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| UPC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.45 | ||
| Sortino ratioReturn per unit of downside risk | +0.94 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.25 | +0.12 |
| Calmar ratioReturn relative to maximum drawdown | -0.14 | 2.00 | -2.14 |
| Martin ratioReturn relative to average drawdown | -0.19 | 8.49 | -8.68 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Universe Pharmaceuticals INC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Universe Pharmaceuticals INC was 99.99%, occurring on Mar 25, 2026. The portfolio has not yet recovered.
The current Universe Pharmaceuticals INC drawdown is 99.98%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.99%Mar 2026 | 4y 11mo | — | 5y 4moApr 2021 - now | — |
-28.52%Mar 2021 | 1d | 5d | 6dMar 2021 - Apr 2021 | — |
-23.00%Mar 2021 | 2d | 4d | 6dMar 2021 - Mar 2021 | — |
Drawdown Indicators
| UPC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -56.78% | -43.21% |
Max Drawdown (1Y)Largest decline over 1 year | -76.24% | -9.10% | -67.14% |
Max Drawdown (3Y)Largest decline over 3 years | -99.91% | -18.90% | -81.01% |
Max Drawdown (5Y)Largest decline over 5 years | -99.98% | -25.43% | -74.55% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.98% | -1.58% | -98.40% |
Average DrawdownAverage peak-to-trough decline | -86.62% | -10.70% | -75.92% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 56.54% | 2.14% | +54.40% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Universe Pharmaceuticals INC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Universe Pharmaceuticals INC is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for UPC relative to other companies in the Biotechnology industry. Currently, UPC has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for UPC in comparison with other companies in the Biotechnology industry. Currently, UPC has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with UPC
Add Universe Pharmaceuticals INC to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with UPC